{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T22:59:19Z","timestamp":1793314759243,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1136\/ijgc-2018-000016","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T14:11:48Z","timestamp":1547475108000},"page":"195-200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Ovarian cancer: screening and future directions"],"prefix":"10.1016","volume":"29","author":[{"given":"Keshav Kumar","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Wendel","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2018-000016_bb0010","author":"National Institute for Health and Care Excellence (NICE)","year":"2011","journal-title":"Ovarian cancer: recognition and initial management"},{"key":"10.1136\/ijgc-2018-000016_bb0015","author":"Office for National Statistics","year":"2016","journal-title":"Cancer survival by stage at diagnosis for England (experimental statistics): Adults diagnosed 2012, 2013 and 2014 and followed up to 2015"},{"key":"10.1136\/ijgc-2018-000016_bb0020","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2214\/ajr.179.4.1790825","article-title":"Screening for preclinical disease: test and disease characteristics","volume":"179","author":"Herman","year":"2002","journal-title":"AJR Am J Roentgenol"},{"key":"10.1136\/ijgc-2018-000016_bb0025","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2217\/17520363.1.4.513","article-title":"CA125 in ovarian cancer","volume":"1","author":"Scholler","year":"2007","journal-title":"Biomark Med"},{"key":"10.1136\/ijgc-2018-000016_bb0030","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJM198310133091503","article-title":"A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer","volume":"309","author":"Bast","year":"1983","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2018-000016_bb0035","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1001\/jama.2011.766","article-title":"Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial","volume":"305","author":"Buys","year":"2011","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2018-000016_bb0040","first-page":"9","article-title":"In search of the ideal tumor marker for epithelial ovarian cancer: serum antigen CA-125 versus HE4, and others; current status and clinical utility","volume":"1","author":"Morales-V\u00e1squez","year":"2014","journal-title":"J Cancerology"},{"key":"10.1136\/ijgc-2018-000016_bb0045","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1158\/1940-6207.CAPR-11-0378","article-title":"Personalizing CA125 levels for ovarian cancer screening","volume":"4","author":"Dorigo","year":"2011","journal-title":"Cancer Prev Res"},{"key":"10.1136\/ijgc-2018-000016_bb0050","article-title":"CA 125 and epithelial ovarian cancer: role in screening, diagnosis, and surveillance","volume":"10","author":"Pepin","year":"2014","journal-title":"Am J Hematol\/Oncol"},{"key":"10.1136\/ijgc-2018-000016_bb0055","author":"US Preventive Task Force","year":"2013","journal-title":"Ovarian cancer: screening"},{"key":"10.1136\/ijgc-2018-000016_bb0060","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1097\/AOG.0b013e318238d030","article-title":"Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening","volume":"118","author":"van Nagell","year":"2011","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2018-000016_bb0065","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.ygyno.2013.11.030","article-title":"Ovarian cancer screening--current status, future directions","volume":"132","author":"Menon","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2018-000016_bb0070","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/aje\/kwk075","article-title":"Evidence of a healthy volunteer effect in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial","volume":"165","author":"Pinsky","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1136\/ijgc-2018-000016_bb0075","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1525-1438.2007.01035.x","article-title":"A randomized study of screening for ovarian cancer: a multicenter study in Japan","volume":"18","author":"Kobayashi","year":"2008","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2018-000016_bb0080","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0140-6736(15)01224-6","article-title":"Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial","volume":"387","author":"Jacobs","year":"2016","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2018-000016_bb0085","author":"U.S. Food and Drug Administration","year":"2016","journal-title":"Ovarian cancer screening tests: safety communication - FDA recommends against use"},{"key":"10.1136\/ijgc-2018-000016_bb0090","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1200\/JCO.2004.07.179","article-title":"Biology of epithelial ovarian cancer: implications for screening women at high genetic risk","volume":"22","author":"Hogg","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2018-000016_bb0095","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1001\/jamaoncol.2017.4211","article-title":"Estimating cost-effectiveness of a multimodal ovarian cancer screening program in the United States: secondary analysis of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS)","volume":"4","author":"Moss","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2018-000016_bb0100","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","article-title":"Markov models in medical decision making: a practical guide","volume":"13","author":"Sonnenberg","year":"1993","journal-title":"Med Decis Making"},{"key":"10.1136\/ijgc-2018-000016_bb0105","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ygyno.2018.01.029","article-title":"Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): good, bad, or just expensive?","volume":"149","author":"Naumann","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2018-000016_bb0110","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.currproblcancer.2017.12.005","article-title":"Screening program in ovarian cancer: a logical step in clinical management? A meta-analysis","volume":"42","author":"Marchetti","year":"2018","journal-title":"Curr Probl Cancer"},{"key":"10.1136\/ijgc-2018-000016_bb0115","doi-asserted-by":"crossref","first-page":"6890","DOI":"10.1200\/JCO.2005.02.626","article-title":"Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer","volume":"23","author":"Madalinska","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2018-000016_bb0120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1158\/1940-6207.CAPR-10-0195","article-title":"Ovarian cancer biomarker performance in Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial specimens","volume":"4","author":"Cramer","year":"2011","journal-title":"Cancer Prev Res"},{"key":"10.1136\/ijgc-2018-000016_bb0125","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ygyno.2016.01.016","article-title":"HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: an Italian multicenter study","volume":"141","author":"Romagnolo","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2018-000016_bb0130","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/jclinpath-2012-201031","article-title":"Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review","volume":"66","author":"Ferraro","year":"2013","journal-title":"J Clin Pathol"},{"key":"10.1136\/ijgc-2018-000016_bb0135","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1097\/IGC.0000000000000192","article-title":"Accuracy of serum human epididymis protein 4 in ovarian cancer diagnosis: a systematic review and meta-analysis","volume":"24","author":"Macedo","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2018-000016_bb0140","first-page":"289","article-title":"Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks","volume":"8","author":"Timms","year":"2011","journal-title":"Cancer Genomics Proteomics"},{"key":"10.1136\/ijgc-2018-000016_bb0145","article-title":"Abstract AP01: HE4 is a biomarker for newly diagnosed and recurrent high-grade serous ovarian cancers with normal CA-125 values","author":"LaVigne","year":"2017","journal-title":"AACR"},{"key":"10.1136\/ijgc-2018-000016_bb0150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ygyno.2005.11.015","article-title":"Ultrasound characteristics of different types of adnexal malignancies","volume":"102","author":"Valentin","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2018-000016_bb0155","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1200\/JCO.2016.70.8594","article-title":"Ultrasound molecular imaging with BR55 in patients with breast and ovarian lesions: first-in-human results","volume":"35","author":"Willmann","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2018-000016_bb0160","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00962-1","article-title":"High grade serous ovarian carcinomas originate in the fallopian tube","volume":"8","author":"Labidi-Galy","year":"2017","journal-title":"Nat Commun"},{"key":"10.1136\/ijgc-2018-000016_bb0165","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-016-0354-x","article-title":"Cytologic studies of the fallopian tube in patients undergoing salpingo-oophorectomy","volume":"16","author":"Chen","year":"2016","journal-title":"Cancer Cell Int"},{"key":"10.1136\/ijgc-2018-000016_bb0170","article-title":"Tubal cytology of the fallopian tube as a promising tool for ovarian cancer early detection","volume":"125","author":"Chen","year":"2017","journal-title":"J Vis Exp"},{"key":"10.1136\/ijgc-2018-000016_bb0175","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/bjc.2013.402","article-title":"Early detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavity","volume":"109","author":"Otsuka","year":"2013","journal-title":"Br J Cancer"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24010417?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24010417?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2018-000016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:37:43Z","timestamp":1753101463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24010417"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S1048891X24010417"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2018-000016","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ovarian cancer: screening and future directions","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2018-000016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 IGCS and ESGO 2019. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}